Modular Nanoparticle Vaccine Composition for Targeted Immune Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine technologies face challenges in effectively addressing infectious diseases such as malaria and HIV due to limited development of vaccines that efficiently prime cell-mediated immunity, lack of tunable adjuvants, and difficulties in administration, especially in underdeveloped countries with limited resources and cold storage capabilities, as well as the need for oral vaccines targeting both systemic and mucosal immunity.
Innovation Solution
Modular nanoparticle vaccine compositions that allow flexible addition and subtraction of antigens, adjuvants, and immune potentiators, with targeted delivery to specific immune cells, enabling optimal immune response modulation and enhanced stability for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional adjuvants (colloidal alum, montanide polymers) are used to enhance immune response, then antibody serum titers are increased, but cellular and mucosal immune responses are ineffective
Solution Approach 1:
The vaccine system is segmented into distinct functional modules: adjuvant module for immune potentiation, antigen module for immunogenicity, and delivery vehicle module for targeted transport. This segmentation allows each module to be optimized independently - the adjuvant can be designed to provide both humoral and cellular stimulation, while the delivery vehicle ensures mucosal and tissue-specific targeting, thereby resolving the limitation of traditional single-function adjuvants.
Solution Approach 2:
The delivery vehicle is designed as a multi-functional platform that simultaneously provides: (1) targeted delivery to specific tissue compartments (mucosal, lymphoid, cellular), (2) controlled release of antigen and adjuvant, (3) enhancement of both humoral and cellular immune responses, and (4) stabilization of antigen. This multi-functionality eliminates the need for separate adjuvants and delivery systems, directly addressing the contradiction between antibody titer enhancement and cellular/mucosal response effectiveness.
2Stability of the object's composition
If purified antigen subunits are used in vaccines, then production stability is improved, but immunogenicity decreases compared to whole pathogens
Solution Approach 1:
The invention merges purified antigen subunits with a delivery vehicle that provides adjuvant activity and controlled release characteristics. This combination restores the immunogenicity of purified antigens by delivering them in a formulation that mimics the structural and functional properties of whole pathogens, thereby achieving both production stability and high immunogenicity simultaneously.
Solution Approach 2:
The delivery vehicle acts as an intermediary between the purified antigen and the immune system. It facilitates the interaction by providing a structured platform that enhances antigen presentation, promotes both humoral and cellular responses, and maintains antigen stability. This intermediary function compensates for the reduced immunogenicity of purified antigens while preserving production stability.
3Reliability
If live attenuated vaccines are used to induce strong immune response, then immune potency is improved, but safety risks and manufacturing complexity increase
Solution Approach 1:
The invention extracts the essential immunogenic components from live attenuated vaccines - specifically the antigenic subunits - and delivers them via a controlled release formulation. This extraction approach maintains the immune response strength of live vaccines while eliminating the safety risks and manufacturing complexities associated with live attenuated strains, as the vaccine consists of stabilized purified proteins or peptides rather than replicating pathogens.
4Ease of manufacture
If aluminum salts are used as adjuvants, then ease of manufacture is improved, but allergic side effects and limited immunostimulatory properties occur
Solution Approach 1:
The invention changes the chemical and functional parameters of the adjuvant system by replacing aluminum salts with a delivery vehicle based on stabilized proteins or peptides. This parameter change maintains ease of manufacture through standardized purification and formulation processes, while eliminating allergic side effects associated with aluminum salts and providing enhanced immunostimulatory properties through the protein-based adjuvant activity.
Data Source
AI summary
Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.